Product Information Sheet for NR-9693

Influenza A Virus, A/Solomon Islands/3/06 (HA, NA) x A/Puerto Rico/8/34 (H1N1), Reassortant IVR-145

Catalog No. NR-9693

This reagent is the tangible property of the U.S. Government.

For research use only. Not for human use.

Contributor:

Alexander Klimov, Ph.D., Chief, Viral Surveillance and Diagnostic Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Coordinating Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia

Product Description:

Virus Classification: *Orthomyxoviridae, Influenzavirus A*
Species: Influenza A virus
Strains/Isolates: A/Solomon Islands/3/06 (HA, NA) x A/Puerto Rico/8/34 (H1N1), Reassortant IVR-145
Preparation: Reassortant between A/Solomon Islands/3/06 (H1N1) and reassortant IVR-6.[1] IVR-6 is a reassortant between A/Texas/77 (H3N2) and A/Puerto Rico/8/34 (H1N1).[2] The HA and NA proteins of reassortant IVR-145 are from A/Solomon Islands/3/06 (H1N1).
Comments: Influenza A/Solomon Islands/3/06 (H1N1) was originally isolated on August 21, 2006 from a human nasal swab in the Solomon Islands in the South Pacific[3]. Influenza A/Solomon Islands/3/06 (H1N1)-like viruses were used as the influenza A (H1N1) component of the 2007-2008 vaccine for the northern hemisphere[4] and the 2008 vaccine for the southern hemisphere.[5]

Material Provided:

Each vial contains approximately 1 mL of pooled allantoic fluid from specific-pathogen free (SPF) embryonated chicken eggs infected with recombinant influenza A virus, A/Solomon Islands/3/06 (HA, NA) x A/Puerto Rico/8/34 (H1N1), Reassortant IVR-145.

Note: If homogeneity is required for your intended use, please purify prior to initiating work.

Packaging/Storage:

NR-9693 was packaged aseptically in screw-capped plastic cryovials. The product is provided frozen and should be stored at -70°C or colder immediately upon arrival. For long-term storage, the vapor phase of a liquid nitrogen freezer is recommended. Freeze-thaw cycles should be avoided.

Growth Conditions:

Host: 9 to 11-day-old SPF embryonated chicken eggs
Infection: Embryonated chicken eggs must be candled for viability prior to inoculation
Incubation: 1 to 3 days at 33 to 35°C in a humidified chamber without CO_2
Effect: Hemagglutination activity using chicken red blood cells and allantoic fluid from infected embryonated chicken eggs

Citation:

Acknowledgment for publications should read "The following reagent was obtained through the NIH Biodefense and Emerging Infections Research Resources Repository, NIAID, NIH: Influenza A Virus, A/Solomon Islands/3/06 (HA, NA) x A/Puerto Rico/8/34 (H1N1), Reassortant IVR-145, NR-9693."

Biosafety Level: 2

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 5th ed. Washington, DC: U.S. Government Printing Office, 2007; see www.cdc.gov/od/ohs/biosfty/bmbl5/bmbl5toc.htm.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government make any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

Biodefense and Emerging Infections Research Resources Repository
P.O. Box 4137
Manassas, VA 20108-4137 USA
www.beiresources.org
800-359-7370
Fax: 703-365-2898
E-mail: contact@beiresources.org

References:

1. http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm127192.htm
2. Nicolson, C. et al. "Generation of Influenza Vaccine Viruses on Vero Cells by Reverse Genetics: An H5N1 Candidate Vaccine Strain Produced Under a Quality System." Vaccine 23 (2005): 2943-2952. PubMed: 15780743.
3. Dr. Alexander Klimov, personal communication.
4. World Health Organization. "Recommended Composition of Influenza Virus Vaccines for Use in the 2007-2008 Influenza Season." Wkly. Epidemiol. Rec. 82 (2007): 69-74. PubMed: 17333570.
5. World Health Organization. "Recommended Composition of Influenza Virus Vaccines for Use in the 2008 Influenza Season." Wkly. Epidemiol. Rec. 82 (2007): 351-356. PubMed: 17918656.

Support Provided by NIAID

Biodefense and Emerging Infections Research Resources Repository
P.O. Box 4137
Manassas, VA 20108-4137 USA
www.beiresources.org

800-359-7370
Fax: 703-365-2898
E-mail: contact@beiresources.org